Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 27

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 27
---
 to key corporate transactions, including potential collaborations and licensing arrangements. The primary function of this ad hoc committee is to confer on such matters with the Chief Executive Officer and the Company’s corporate development, finance and legal leadership teams. The members of the ad hoc Transactions Committee are Dr. Gallagher, and Messrs. Heiden and Mallik, each

<div align='center'>15</div>

of whom have significant expertise in structuring, evaluating and advising on biotechnology collaboration and licensing transactions. Summary of Current Director Core Experiences, Skills and Board Tenure Our Board members are a diverse group of highly qualified leaders in their respective fields. Most of our directors have senior leadership experience at large public and private companies and have significant and diverse management experience (including strategic, planning, financial reporting, compliance, risk management, leadership development, scientific and healthcare industry expertise). The Board believes the skills, qualities, attributes, experience and diversity of our directors provide us with a range of perspectives to effectively represent the best interests of our stockholders. The chart below summarizes our directors’ strengths.

| Experience / Skills*                      | Nguyen | Touchon | Ciongoli | Fust | Gallagher | Heiden | Mallik | Roncarolo |
| Healthcare Industry, Providers and Payers |        |       ✓ |          |    ✓ |         ✓ |      ✓ |      ✓ |           |
| Research and Development                  |      ✓ |       ✓ |          |      |         ✓ |        |        |         ✓ |
| Regulatory / Compliance                   |      ✓ |       ✓ |          |    ✓ |         ✓ |        |      ✓ |         ✓ |
| Public Company Governance                 |        |       ✓ |        ✓ |    ✓ |         ✓ |      ✓ |      ✓ |         ✓ |
| Financial / Accounting                    |        |       ✓ |        ✓ |    ✓ |         ✓ |      ✓ |      ✓ |           |
| Executive Leadership                      |      ✓ |       ✓ |        ✓ |    ✓ |         ✓ |      ✓ |      ✓ |         ✓ |
| M&A / Transactions                        |      ✓ |       ✓ |        ✓ |    ✓ |         ✓ |      ✓ |      ✓ |           |
| Board Tenure(Year Joined)                 |   2024 |    2019 |     2024 | 2014 |      2013 |   2015 |   2021 |      2020 |

*The lack of a mark for a particular item does not mean the director does not